Associated tags: Adrenocortical carcinoma, Cancer, Lung cancer, Breast cancer, Radiopharmaceutical, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, Health, Pharmaceutical industry, Assistant, Acute leukemia, Prostate cancer, Merrimack Pharmaceuticals, Sorafenib, Wake Forest University School of Law, Oncology, Myelodysplastic syndrome, Semmelweis University, Knowledge, Drug, Bayer
Locations: CALIFORNIA, UNITED STATES, NORTH AMERICA, AURORA
Retrieved on:
Wednesday, January 3, 2024
Health,
Science,
Radiology,
Other Science,
Oncology,
Aurora Biosciences,
Multimedia,
Knowledge,
Vertex Pharmaceuticals,
GPCR,
Destiny,
Cancer,
Radiopharmaceutical,
Pharmacology,
G protein-coupled receptor Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing.
Key Points:
- Radionetics Oncology, Inc. , a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing.
- Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.
- He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics.
- “The spatial biology and pharmacology of GPCRs makes them ideal for small molecule radiopharmaceutical development, opening a new chapter for the field.”
Retrieved on:
Tuesday, October 17, 2023
Oncology,
Health,
Clinical Trials,
Radiology,
Pharmaceutical,
Biotechnology,
MC2R,
Biology,
Trial of the century,
Carcinoma,
Safety,
University,
Radiopharmaceutical,
Disease,
University of Michigan Rogel Cancer Center,
FDA,
Glomus tumor,
Adrenocortical carcinoma,
G protein-coupled receptor,
Patient,
Medical imaging,
Pharmaceutical industry Study R8760-101 (NCT05999292) is evaluating the safety and dosimetry of 68Ga-R8760, a first-in-class small molecule radioligand imaging agent being developed for patients diagnosed with adrenocortical carcinoma.
Key Points:
- Study R8760-101 (NCT05999292) is evaluating the safety and dosimetry of 68Ga-R8760, a first-in-class small molecule radioligand imaging agent being developed for patients diagnosed with adrenocortical carcinoma.
- 68Ga-R8760 was discovered by Radionetics Oncology for identifying melanocortin 2 receptor (MC2R)-expressing adrenocortical cancer lesions to select patients who may benefit from MC2R-directed radioconjugate therapy.
- The multi-center study is being conducted in the United States in collaboration with global leaders in the treatment of adrenocortical carcinoma.
- MC2R is highly expressed on adrenocortical carcinoma tumors with limited expression in healthy tissue outside of the adrenal gland itself.
Retrieved on:
Wednesday, February 22, 2023
Medical Devices,
Hospitals,
Clinical Trials,
Cardiology,
Biotechnology,
Radiology,
Health,
Pharmaceutical,
General Health,
Knowledge,
Irinotecan,
Acute leukemia,
Cancer,
Prostate cancer,
Merrimack Pharmaceuticals,
Sorafenib,
Wake Forest University School of Law,
Assistant,
Radiopharmaceutical,
Myelodysplastic syndrome,
Semmelweis University,
Drug,
Bayer,
Wake Forest University,
Therapy,
Haematopoietic system,
Wake Forest School of Medicine,
Pharmaceutical industry,
Medicine Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is pleased to announce the appointment of Istvan Molnar, M.D.
Key Points:
- Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is pleased to announce the appointment of Istvan Molnar, M.D.
- as Chief Medical Officer.
- Dr. Molnar is an industry veteran bringing 15 years of experience in oncology clinical development, including significant expertise in radiopharmaceutical drug development.
- Dr. Molnar has a broad background in oncology and radiopharmaceutical drug development spanning early- to late-stage projects with extensive global experience in clinical development, regulatory, medical affairs, and drug safety.
